Jasper Therapeutics doses first patient in chronic inducible urticaria study
Click Here to Manage Email Alerts
Key takeaways:
- The phase 1b/2a study, SPOTLIGHT, will evaluate subcutaneous briquilimab for the treatment of chronic inducible urticaria.
- Briquilimab is a novel antibody therapy that targets c-Kit in mast cell driven diseases.
The first patient has been dosed in Jasper Therapeutic’s phase 1b/2a SPOTLIGHT clinical trial of subcutaneous briquilimab for the treatment of chronic inducible urticaria, the company announced in a press release.
Briquilimab is a novel antibody therapy targeting c-Kit in mast cell driven diseases such as chronic spontaneous urticaria and chronic inducible urticaria (CIndU). The subcutaneous, single administration treatment is being evaluated in SPOTLIGHT under two different dose levels for adults with cold urticaria or symptomatic dermographism, two subtypes of CIndU.
“We are excited to announce dosing of the first patient in the SPOTLIGHT study in patients with CIndU, our second clinical program evaluating briquilimab in a mast cell-mediated disease,” Edwin Tucker, MD, MBA, chief medical officer of Jasper, said in the release. “As with our BEACON study in [chronic spontaneous urticaria], we expect the SPOTLIGHT study to establish proof of concept for the depletion of mast cells by briquilimab in CIndU and help us to determine doses and dosing regimens for future registrational studies.”
Including the patient that has just been dosed, Jasper expects to enroll a total of 15 patients across the two dosage cohorts. The primary endpoints of the study include data demonstrating briquilimab is safe and tolerable for patients. Secondary endpoints include efficacy measures and pharmacokinetics.
According to the press release, Jasper expects to release preliminary data from the SPOTLIGHT study in the second half of 2024.